Eli Lilly and Company
LLY
$732.41
$11.501.60%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 4.41B | 970.30M | 2.97B | 2.24B | 2.19B |
| Total Depreciation and Amortization | 484.80M | 466.80M | 414.40M | 400.60M | 387.70M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -195.90M | 2.28B | -516.10M | 273.70M | 282.90M |
| Change in Net Operating Assets | -2.22B | -9.80M | -1.40B | -1.75B | -3.17B |
| Cash from Operations | 2.47B | 3.71B | 1.47B | 1.17B | -311.90M |
| Capital Expenditure | -1.50B | -1.35B | -1.22B | -986.30M | -1.07B |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | 0.00 | -947.70M | -- | -1.04B |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -424.50M | -2.65B | -26.20M | -191.30M | -809.40M |
| Cash from Investing | -1.92B | -4.00B | -2.20B | -1.18B | -2.92B |
| Total Debt Issued | 0.00 | 4.96B | 0.00 | 6.45B | 4.59B |
| Total Debt Repaid | 3.04B | -3.09B | 2.74B | -5.20B | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -2.05B | -446.10M | -- | -- | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -1.17B | -1.17B | -1.17B | -1.17B | -1.02B |
| Other Financing Activities | -45.50M | -47.30M | -8.00M | -389.80M | -31.60M |
| Cash from Financing | -225.40M | 211.30M | 1.56B | -311.30M | 3.54B |
| Foreign Exchange rate Adjustments | -428.50M | 226.90M | -59.60M | -35.50M | 129.30M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -100.60M | 145.40M | 763.40M | -358.40M | 437.80M |
